1-8 of 8
Karen Gelmon
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase 1/2 Study of the Indoleamine 2,3-Dioxygenase 1 Inhibitor Linrodostat Mesylate Combined with Nivolumab or Nivolumab and Ipilimumab in Advanced Solid Tumors or Hematologic Malignancies

Jason J. Luke, Karen Gelmon, Lillian L. Siu, Victor Moreno, Jayesh Desai, Carlos A. Gomez-Roca, Matteo S. Carlino, Russell K. Pachynski, Rasha Cosman, Quincy Siu-Chung Chu, Silvia Damian, Giuseppe Curigliano, Rachel Tam, Xianling Wang, Chandrika Jeyamohan, Lily Wang, Li Zhu, Julia Santucci-Pereira, Danielle M. Greenawalt, Josep Tabernero
Journal: Clinical Cancer Research
Clin Cancer Res OF1–OF11.
https://doi.org/10.1158/1078-0432.CCR-24-0439
Published: 07 January 2025
View article titled, Phase 1/2 Study of the Indoleamine 2,3-Dioxygenase 1 Inhibitor Linrodostat Mesylate Combined with Nivolumab or Nivolumab and Ipilimumab in Advanced Solid Tumors or Hematologic Malignancies
Open the PDF for Phase 1/2 Study of the Indoleamine 2,3-Dioxygenase 1 Inhibitor Linrodostat Mesylate Combined with Nivolumab or Nivolumab and Ipilimumab in Advanced Solid Tumors or Hematologic Malignancies in another window
Includes: Supplementary data
Journal Articles

Homologous Recombination Deficiency and Platinum-Based Therapy Outcomes in Advanced Breast Cancer

Eric Y. Zhao, Yaoqing Shen, Erin Pleasance, Katayoon Kasaian, Sreeja Leelakumari, Martin Jones, Pinaki Bose, Carolyn Ch'ng, Caralyn Reisle, Peter Eirew, Richard Corbett, Karen L. Mungall, Nina Thiessen, Yussanne Ma, Jacqueline E. Schein, Andrew J. Mungall, Yongjun Zhao, Richard A. Moore, Wendie Den Brok, Sheridan Wilson, Diego Villa, Tamara Shenkier, Caroline Lohrisch, Stephen Chia, Stephen Yip, Karen Gelmon, Howard Lim, Daniel Renouf, Sophie Sun, Kasmintan A. Schrader, Sean Young, Ian Bosdet, Aly Karsan, Janessa Laskin, Marco A. Marra, Steven J.M. Jones
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (24): 7521–7530.
https://doi.org/10.1158/1078-0432.CCR-17-1941
Published: 14 December 2017
View article titled, Homologous Recombination Deficiency and Platinum-Based Therapy Outcomes in Advanced Breast Cancer
Open the PDF for Homologous Recombination Deficiency and Platinum-Based Therapy Outcomes in Advanced Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Preclinical Efficacy and Safety Assessment of an Antibody–Drug Conjugate Targeting the c-RET Proto-Oncogene for Breast Carcinoma

Minh Nguyen, Shuichi Miyakawa, Junichi Kato, Toshiyuki Mori, Toshimitsu Arai, Mark Armanini, Karen Gelmon, Rinat Yerushalmi, Samuel Leung, Dongxia Gao, Gregory Landes, Mary Haak-Frendscho, Kathleen Elias, Andrew D. Simmons
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (24): 5552–5562.
https://doi.org/10.1158/1078-0432.CCR-15-0468
Published: 14 December 2015
View article titled, Preclinical Efficacy and Safety Assessment of an Antibody–Drug Conjugate Targeting the c-RET Proto-Oncogene for Breast Carcinoma
Open the PDF for Preclinical Efficacy and Safety Assessment of an Antibody–Drug Conjugate Targeting the c-RET Proto-Oncogene for Breast Carcinoma in another window
Includes: Supplementary data
Journal Articles

A new enrichment model for high sensitivity detection and downstream analyses of circulating tumor cells in breast cancer patients

Glenn Deng, Moshe Mishaeli, Melinda Miller, David Huntsman, Karen Gelmon, Rinat Yerushalmi, Edward Manna, David Krag, Jerry Williamson, Julian Burke
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (15_Supplement): B19.
Published: 15 August 2014
View article titled, A new enrichment model for high sensitivity detection and downstream analyses of circulating tumor cells in breast cancer patients
Journal Articles

Autophagy Inhibition Augments the Anticancer Effects of Epirubicin Treatment in Anthracycline-Sensitive and -Resistant Triple-Negative Breast Cancer

Suganthi Chittaranjan, Svetlana Bortnik, Wieslawa H. Dragowska, Jing Xu, Namal Abeysundara, Amy Leung, Nancy E. Go, Lindsay DeVorkin, Sherry A. Weppler, Karen Gelmon, Donald T. Yapp, Marcel B. Bally, Sharon M. Gorski
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2014) 20 (12): 3159–3173.
https://doi.org/10.1158/1078-0432.CCR-13-2060
Published: 12 June 2014
View article titled, Autophagy Inhibition Augments the Anticancer Effects of Epirubicin Treatment in Anthracycline-Sensitive and -Resistant Triple-Negative Breast Cancer
Open the PDF for Autophagy Inhibition Augments the Anticancer Effects of Epirubicin Treatment in Anthracycline-Sensitive and -Resistant Triple-Negative Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Phase II Trial of OGX-011 in Combination with Docetaxel in Metastatic Breast Cancer

Stephen Chia, Susan Dent, Susan Ellard, Peter M. Ellis, Ted Vandenberg, Karen Gelmon, Jean Powers, Wendy Walsh, Lesley Seymour, Elizabeth A. Eisenhauer
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (2): 708–713.
https://doi.org/10.1158/1078-0432.CCR-08-1159
Published: 15 January 2009
View article titled, Phase II Trial of OGX-011 in Combination with Docetaxel in Metastatic Breast Cancer
Open the PDF for Phase II Trial of OGX-011 in Combination with Docetaxel in Metastatic Breast Cancer in another window
Journal Articles

First Study of the Safety, Tolerability, and Pharmacokinetics of CP-724,714 in Patients with Advanced Malignant Solid HER2-Expressing Tumors

Pamela N. Munster, Carolyn D. Britten, Monica Mita, Karen Gelmon, Susan E. Minton, Stacy Moulder, Dennis J. Slamon, Feng Guo, Stephen P. Letrent, Louis Denis, Anthony W. Tolcher
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (4): 1238–1245.
https://doi.org/10.1158/1078-0432.CCR-06-1539
Published: 22 February 2007
View article titled, First Study of the Safety, Tolerability, and Pharmacokinetics of CP-724,714 in Patients with Advanced Malignant Solid HER2-Expressing Tumors
Open the PDF for First Study of the Safety, Tolerability, and Pharmacokinetics of CP-724,714 in Patients with Advanced Malignant Solid HER2-Expressing Tumors in another window
Journal Articles

Treatment of HER-2/ neu Overexpressing Breast Cancer Xenograft Models with Trastuzumab (Herceptin) and Gefitinib (ZD1839): Drug Combination Effects on Tumor Growth, HER-2/ neu and Epidermal Growth Factor Receptor Expression, and Viable Hypoxic Cell Fraction

Corinna Warburton, Wieslawa H. Dragowska, Karen Gelmon, Stephen Chia, Hong Yan, Dana Masin, Tetyana Denyssevych, Anne E. Wallis, Marcel B. Bally
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (7): 2512–2524.
https://doi.org/10.1158/1078-0432.CCR-03-0244
Published: 08 April 2004
View article titled, Treatment of HER-2/ <em>neu</em> Overexpressing Breast Cancer Xenograft Models with Trastuzumab (Herceptin) and Gefitinib (ZD1839): Drug Combination Effects on Tumor Growth, HER-2/ <em>neu</em> and Epidermal Growth Factor Receptor Expression, and Viable Hypoxic Cell Fraction
Open the PDF for Treatment of HER-2/ <em>neu</em> Overexpressing Breast Cancer Xenograft Models with Trastuzumab (Herceptin) and Gefitinib (ZD1839): Drug Combination Effects on Tumor Growth, HER-2/ <em>neu</em> and Epidermal Growth Factor Receptor Expression, and Viable Hypoxic Cell Fraction in another window